2011
DOI: 10.1038/nrneurol.2011.76
|View full text |Cite
|
Sign up to set email alerts
|

The ethics of informed consent in Alzheimer disease research

Abstract: Clinical research on Alzheimer disease (AD) is much needed but requires the participation of patients with substantial cognitive impairment who have difficulty providing informed consent. Despite decades of debate, policies regulating such research are not well-defined. Although numerous studies have underscored the difficulties of obtaining informed consent for clinical research from patients compromised by AD, there is also increasing evidence that such individuals and their surrogates can make decisions abo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
45
0
1

Year Published

2013
2013
2023
2023

Publication Types

Select...
6
2
2

Relationship

0
10

Authors

Journals

citations
Cited by 57 publications
(49 citation statements)
references
References 36 publications
3
45
0
1
Order By: Relevance
“…Such use of surrogate decision-makers should represent extremely rare cases. It requires special vigilance as surrogates may, on purpose or unknowingly, pursue their own interests at the expense of the patient 16. Local legislation may govern such clinical situations in different countries 17 18.…”
Section: Methodsmentioning
confidence: 99%
“…Such use of surrogate decision-makers should represent extremely rare cases. It requires special vigilance as surrogates may, on purpose or unknowingly, pursue their own interests at the expense of the patient 16. Local legislation may govern such clinical situations in different countries 17 18.…”
Section: Methodsmentioning
confidence: 99%
“…This is similar to the framework developed by Grisso and Appelbaum,12 which is widely used in the US and other jurisdictions. Studies using the functional capacity framework show that most patients with Alzheimer’s disease are incapable of making treatment and research decisions,13 including simple decisions regarding medication for Alzheimer’s disease 14. Even mild cognitive impairment (a condition that precedes Alzheimer’s disease by 3–4 years15) can cause significant impairment in decision making,16 with 40% of patients lacking capacity for research decisions 17.…”
Section: Discussionmentioning
confidence: 99%
“…This might be due to regulations of data protection and legal requirements concerning confidential medical communication, which may be complicated with demented residents, who often have legal representatives 33 .…”
Section: Discussionmentioning
confidence: 99%